LUXEMBOURG, April 20, 2016 /PRNewswire/ -- ConvaTec Inc., a leading global medical products and technologies company, announced today that the Regional German Court of Dusseldorf affirmed that a competitor's product infringes the European patent EP 1 547 639 B1 owned by ConvaTec Technologies Inc. The patent is related to ConvaTec's Flexi-Seal™ Fecal Management System, a temporary containment device, indicated for bedridden or immobilized, incontinent patients with liquid or semi-liquid stool.
Amongst other rulings, the judgment ordered the competitor to cease and desist from placing on the market its product; to recall its product; and to compensate ConvaTec.
"We are pleased by the Court's ruling," said Mads Haugaard, Vice President and General Manager of ConvaTec's Continence & Critical Care business. "The decision validates the solid patents we have protecting our innovative portfolio and enables us to continue our focus on advancing the standard of care for patients everywhere. In that context, respect for our important intellectual property remains a core principle that we continuously and vigorously defend."
About the Continence & Critical Care Business at ConvaTec
Flexi-Seal™ Fecal Management System (FMS) is a temporary containment device, indicated for bedridden or immobilized, incontinent patients with liquid or semi-liquid stool. It is designed to effectively contain and divert fecal matter, which may help to protect patients' wounds from fecal contamination and may help to reduce both the risk of skin breakdown and spread of infection. This easy-to-use system provides an excellent alternative to traditional methods of managing fecal incontinence such as pads, diapers, fecal pouches, and rectal tubes.
More information about the company and its products can be found at www.convatec.com
About ConvaTec ConvaTec is a global medical products and technologies company with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. ConvaTec is owned by Nordic Capital and Avista Capital Partners.
Flexi-Seal is a trade mark of ConvaTec Inc.
© 2016 ConvaTec Inc.